2026 NPPES data Hematology & Oncology Physician NPI 1023698388 MD, PHD
Verify on CMS →

Alexander Salter, MD, PHD

Hematology & Oncology Physician in Palo Alto, California.

This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,232 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.

Federal data, no proprietary rating. We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
92
Medicare Part D claims · 36 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
76%
generic claims · 24% brand-name · higher generic rates reduce patient out-of-pocket costs

What the federal data shows

Alexander Salter, MD, PHD filed 92 Medicare Part D claims in 2023 as a Hematology & Oncology Physician in Palo Alto, California, prescribing 76% generic.

92
Part D claims, 2023
76%
generic prescribing

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.

Alexander Salter, MD, PHD's Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023, across all CMS prescribers nationally

92 0th percentile higher than 0% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). This entry sits in this band. 200–400: 182,923 prescribers (13%). Above this entry. 400–600: 90,619 prescribers (7%). Above this entry. 600–800: 56,224 prescribers (4%). Above this entry. 800–1,000: 40,919 prescribers (3%). Above this entry. 1,000–1,200: 31,827 prescribers (2%). Above this entry. 1,200–1,400: 26,224 prescribers (2%). Above this entry. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2K+: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board-eligible specialty (heuristic, not verified)

Alexander Salter, MD, PHD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about Alexander Salter, MD, PHD?

Quality data not reported

NPI registry status

Active

Issued 04/12/2021

NPI 1023698388

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,232 US NPIs in this specialty

Medicare Part D claims

92 89% vs specialty avg

2023 prescription claims

Specialty avg: 847

Specialty distribution in California

How Hematology & Oncology Physician compares to other specialties among California providers

California providers
Behavior Technician17.3%Marriage & Family Therapist5.5%Student in an Organized Heal…5%Mental Health Counselor3.9%Pharmacist3.5%Clinical Social Worker3.1%Hematology & Oncology Physic…0.1%
Largest specialties in California (% of in-state providers)

Board certification

Not published by CMS

CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Hematology & Oncology Physician. Verify directly:

How MIPS and board certification work

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

Alexander Salter, MD, PHD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding MD, PHD credentials at 291 CAMPUS DR, Palo Alto, CA, 94305, with a listed phone of (650) 497-8000. NPI 1023698388 was issued on 04/12/2021.

Medicare Part D records for calendar year 2023 show 92 prescription claims written by this provider, covering 36 Medicare beneficiaries and totaling roughly $24K in drug spend, split 24% brand-name and 76% generic by claim count.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,232 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.

Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

291 CAMPUS DR
Palo Alto, CA 94305

Provider Details

NPI 1023698388
Specialty Hematology & Oncology Physician
Credentials MD, PHD
Gender Male
NPI Issued 04/12/2021

License & disciplinary context - California MBC 2023 annual report

Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Alexander Salter, MD, PHD. To verify Alexander Salter, MD, PHD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

Alexander Salter, MD, PHD - brand share 24.0%
Hematology & Oncology Physician average

24% brand-name claims vs 76% generic, on 92 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

92
Total Claims
$24K
Total Drug Cost
36
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
162
Total Day Supply
4,235
Brand vs Generic
24% brand / 76% generic
Brand Drug Cost
$22K
Generic Drug Cost
$2K

Patient Demographics

Average Patient Age
70.4 years
Avg HCC Risk Score
2.05
Gender Split
61% female / 39% male

Hematology & Oncology Physician Overview

How Alexander Salter, MD, PHD fits within the Hematology & Oncology Physician landscape nationally.

11,232
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

Alexander Salter, MD, PHD's 92 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Salter.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Before you book an appointment

Use this federal record as your verification checklist, not as a recommendation.

  • Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
  • Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
  • Weigh a second option: compare this provider with a nearby Hematology & Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers

Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.

Frequently Asked Questions

What is Alexander Salter, MD, PHD's specialty?
Alexander Salter, MD, PHD specializes in Hematology & Oncology Physician and practices in Palo Alto, California. Credentials: MD, PHD.
How much does Alexander Salter, MD, PHD prescribe under Medicare Part D?
In 2023, Alexander Salter, MD, PHD wrote 92 Medicare Part D claims totaling $24K in drug costs for 36 beneficiaries.
Where is Alexander Salter, MD, PHD located?
Alexander Salter, MD, PHD is located at 291 CAMPUS DR, Palo Alto, CA, 94305. Phone: (650) 497-8000.
What is Alexander Salter, MD, PHD's NPI number?
Alexander Salter, MD, PHD's National Provider Identifier (NPI) is 1023698388, issued on 04/12/2021.
Does Alexander Salter, MD, PHD prescribe more brand-name or generic drugs?
Alexander Salter, MD, PHD's prescribing is 24% brand-name and 76% generic drugs by claim count, with $22K in brand drug costs.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,232 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
Does Alexander Salter, MD, PHD accept Medicare?
Alexander Salter, MD, PHD appears in CMS Medicare data with 92 Part D claims and 36 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Alexander Salter, MD, PHD's credentials?
Alexander Salter, MD, PHD's NPI is 1023698388 with credentials MD, PHD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

View source datasets and methodology notes
Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology

Compiled from official public sources by the editorial process.

Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.